You may have come across nalmefene — sold in Europe as Selincro — while researching medications that let you drink less rather than demanding you stop entirely. Maybe you read about its as-needed dosing and wondered whether your doctor could prescribe it. Or maybe you're comparing it to naltrexone and trying to figure out whether they're really different drugs or just different brand names for the same thing. These are exactly the right questions, and the answers matter for what you do next.

The short version: nalmefene is a real, well-studied medication with a genuinely different approach to alcohol use disorder treatment — but if you're in the United States, it isn't available by prescription for this purpose. Understanding why that gap exists, what the drug actually does, and what your alternatives are is what this page is for.

How nalmefene differs from naltrexone

Nalmefene and [1]✓ Verified knowledgenaltrexone(/treatment/medication/naltrexone/) are often mentioned in the same breath because both are opioid-system medications used in AUD treatment. But they are not the same drug, and the difference is clinically meaningful.

Naltrexone works as a pure mu-opioid receptor antagonist. When you drink, your brain releases natural opioid chemicals that bind to mu receptors and produce pleasure and relaxation — a core reason alcohol is reinforcing. Naltrexone blocks those receptors, blunting the reward. It's FDA-approved for AUD in the US, available as a daily pill or a monthly injectable (Vivitrol).

Nalmefene also blocks mu-opioid receptors — so it shares that mechanism. But it has an additional property that sets it apart: it acts as a partial agonist at the kappa-opioid receptor (KOR). This isn't a minor footnote. The kappa system plays a significant role in stress responses, dysphoria (that sense of unease or emotional discomfort), and the negative emotional states that drive what researchers call negative-reinforcement drinking — drinking to escape distress rather than to seek pleasure.

In practical terms, nalmefene may be particularly relevant for people whose drinking is fueled by anxiety, stress, or emotional pain. The kappa partial agonism may modulate those stress-driven craving pathways that pure mu-antagonism alone doesn't fully reach. This is why nalmefene and naltrexone, despite their surface similarity, should not be treated as interchangeable — they may suit different people.

What the as-needed dosing model actually looks like

The most clinically innovative feature of Selincro isn't its receptor profile — it's when you take it.

The standard approach: you take 18 mg orally one to two hours before you expect to drink. If you've already started drinking before remembering, you can still take it as soon as possible. On days when you don't plan to drink, you don't take it at all.

This is a fundamentally different model from daily naltrexone, which maintains constant mu-opioid blockade whether or not you drink that day. The as-needed model is built on a specific logic:

• Targeting the moment of risk. Cravings and drinking decisions aren't evenly distributed across every hour of every day. Intervening right before a drinking occasion is when the drug's action is most relevant.
• Aligning with harm-reduction goals. The model doesn't require or assume you're trying to stop drinking entirely. It supports drinking less on the days when drinking happens — a [2]✓ Verified knowledgeReduction(/addiction/harm-reduction/) framework rather than an abstinence-only one.
• Potentially improving adherence. Some people find daily medication burdensome or stigmatizing. Taking a pill only on anticipated drinking days may feel more manageable for some.
• Conceptual similarity to the Sinclair Method. The Sinclair Method uses naltrexone taken before drinking to gradually extinguish the alcohol-reward association through pharmacological extinction. Nalmefene's EU-approved use is conceptually related — medication before drinking to reduce reinforcement — but uses a pharmacologically distinct drug with different receptor activity.

It's worth naming a tension that some patients raise: the repeated daily decision of whether to take medication before drinking can feel psychologically heavy for some people. The flexibility that makes this model appealing to some is a recurring decision point — a constant reminder of their relationship with alcohol — for others. That's a real consideration worth discussing with your care team.

How nalmefene works in the brain

When you drink, your brain releases endogenous opioids that bind to mu receptors and produce pleasure and relaxation. Nalmefene blocks those receptors, preventing alcohol from triggering the same rewarding response — the same mechanism naltrexone uses.

The kappa side of the story works differently. When kappa receptors are strongly activated, they produce dysphoria, anxiety, and stress-like states — essentially the opposite of reward. This system is implicated in the negative emotional states that emerge during withdrawal and that drive stress-related relapse. Nalmefene's partial agonism at kappa receptors means it activates them to a limited, controlled degree. That partial activation may help modulate dysphoric and stress-driven craving without producing the full aversive effects of a complete kappa agonist.

The combined effect — blocking alcohol's rewarding properties through mu-antagonism while modulating stress-driven craving through kappa partial agonism — is the pharmacological rationale for why nalmefene may suit a different patient profile than naltrexone. People whose drinking is heavily driven by negative emotional states or stress may find this dual mechanism more relevant to their experience.

Nalmefene's half-life is approximately 12 hours, meaning it stays active in the body for roughly half a day after a single dose — a duration well-suited to covering a drinking occasion and the hours that follow. The drug is metabolized primarily in the liver, which is why liver function monitoring remains appropriate during treatment, even though the hepatotoxicity signal appears lower than with naltrexone.

What the clinical trials showed

The European Medicines Agency's 2013 approval of Selincro was based on data from the ESENSE 1, ESENSE 2, and SENSE trials — randomized, placebo-controlled studies sponsored by Lundbeck, the pharmaceutical company that developed Selincro for the AUD indication.

A critical feature of these trials was the choice of primary endpoints. Rather than measuring abstinence — the traditional benchmark in US AUD trials — these trials measured:

• Reduction in heavy drinking days (HDDs): A heavy drinking day is defined as more than 60 grams of pure alcohol for men, or more than 40 grams for women. Reducing the number of these days per month was a co-primary endpoint.
• Reduction in total alcohol consumption (TAC): The overall amount of alcohol consumed, measured in grams per day.

This endpoint choice was a deliberate regulatory decision. The EMA's Committee for Medicinal Products for Human Use accepted these reduction-based endpoints as clinically meaningful — a departure from the abstinence-focused framework that has historically dominated AUD drug development in the United States.

Trials enrolled adults with AUD at high or very high drinking risk levels who did not require immediate detoxification. Participants received nalmefene or placebo on an as-needed basis, combined with psychosocial support. The ESENSE trials ran for six months; SENSE ran for one year. Results showed statistically significant reductions in both heavy drinking days and total alcohol consumption in the nalmefene group compared to placebo. Effect sizes were described as modest but clinically meaningful, particularly in the subgroup of patients who remained at high or very high drinking risk at a second screening visit — a population representing a substantial unmet need in AUD care.

Side effects to know about

Nalmefene is generally considered well-tolerated. The most commonly reported side effects in clinical trials include:

• Nausea — the most frequently reported adverse effect
• Insomnia — particularly around the time of dosing
• Dizziness
• Headache
• Fatigue

Most of these effects are mild to moderate and tend to occur early in treatment, often diminishing with continued use. The as-needed dosing model may help limit cumulative side effect burden compared to daily dosing, since the drug is only taken on anticipated drinking days.

The kappa partial agonism raises a theoretical concern about dysphoria as a side effect. In practice, the partial rather than full agonism appears to limit this, but clinicians should be attentive to mood-related complaints. Nalmefene is contraindicated in patients currently using opioid medications, as it will precipitate opioid withdrawal — the same contraindication that applies to naltrexone.

Why nalmefene isn't available in the US

This is the question most US readers arrive with, and it deserves a clear answer.

Oral nalmefene (Selincro) is not FDA-approved for alcohol use disorder in the United States. The nalmefene products that are FDA-approved in the US — Revex (intravenous) and Opvee (intranasal) — are formulated for reversing opioid overdose in emergency settings. They are not the same as the oral tablet used for AUD in Europe, and they are not used for AUD in US clinical practice.

The reason oral nalmefene didn't receive FDA approval for AUD comes down to regulatory philosophy and endpoint strategy. The FDA has historically favored abstinence as the primary endpoint for AUD drug approval — a framework in which treatment success means stopping drinking entirely. The ESENSE and SENSE trials were designed around reduction endpoints, which aligned with the EMA's harm-reduction framework but didn't fit the FDA's traditional approval pathway.

This reflects a deeper philosophical difference about what constitutes meaningful treatment success. The EU's approach acknowledges that many people with AUD are not ready or able to achieve immediate abstinence, and that reducing consumption is itself a clinically valuable outcome. The US approach has historically been more binary — though this is gradually evolving as harm-reduction frameworks gain traction in American addiction medicine.

The practical consequence: a medication available by prescription in Europe for over a decade, representing a genuinely different pharmacological and dosing approach to AUD, is simply not accessible through standard US prescribing channels for this indication.

What US patients can do instead

If you're in the United States and the as-needed, harm-reduction model appeals to you, you're not out of options — you just need to work within what's available here.

Naltrexone taken before drinking is the closest US equivalent to nalmefene's EU-approved use. The Sinclair Method uses FDA-approved naltrexone taken one to two hours before drinking to gradually extinguish the alcohol-reward association — the same event-contingent logic as Selincro's approved use, with a pharmacologically related but distinct drug. Naltrexone is available as a daily oral pill or as a monthly injectable, and it's one of several medications for alcohol use disorder your doctor can prescribe.

If reduction rather than abstinence is your goal, that's a legitimate treatment target worth discussing openly with an addiction medicine physician or a clinician trained in AUD pharmacotherapy. The fact that nalmefene isn't available in the US doesn't mean your interest in a harm-reduction approach is misplaced — it means the regulatory landscape hasn't caught up with the clinical evidence and the treatment philosophy that evidence supports. Exploring alcohol rehab and treatment options with a clinician who understands harm-reduction frameworks can help you find an approach that fits your actual goals.

How nalmefene fits into a broader treatment plan

The EU label for Selincro doesn't position nalmefene as a standalone treatment. The approved indication pairs the medication with continuous psychosocial support focused on helping patients reduce their drinking. Nalmefene is an adjunct to behavioral change, not a replacement for it.

In practice, this means the medication works best when embedded in a broader care relationship — regular check-ins, motivational support, and goal-setting around drinking reduction. The EU model envisions this support being delivered in primary care settings, making Selincro accessible to people with AUD who might not otherwise engage with specialist addiction services.

Brief alcohol interventions — structured, short conversations between a clinician and patient about drinking patterns and goals — are a natural complement to the as-needed model. The medication addresses pharmacological reinforcement; the brief intervention addresses motivation, self-monitoring, and behavioral strategies. Together, they represent a comprehensive approach that meets people where they are rather than requiring abstinence as a precondition for treatment.

What the evidence still doesn't answer

Honesty about evidence gaps is part of trustworthy clinical guidance. Here are the most significant open questions about nalmefene for AUD:

• No head-to-head trial against naltrexone. The most clinically pressing unanswered question is whether nalmefene offers meaningful advantages over naltrexone in equivalent patient populations. Without a direct comparative effectiveness trial, clinicians can't make fully evidence-based choices between these two drugs for a specific patient.
• No long-term outcome data beyond two years. The pivotal trials ran for six months to one year. The long-term trajectory — sustained drinking reduction, progression to abstinence, relapse rates, quality of life — is not well characterized.
• Patient subgroup identification. Which patients benefit most from kappa-active versus pure mu-antagonist therapy hasn't been answered. Identifying clinical profiles or drinking patterns that predict differential response would substantially advance personalized AUD pharmacotherapy.
• Patient-reported experience with PRN dosing. Qualitative research on how patients actually experience the as-needed model — its psychological burden, its fit with daily life, its acceptability across cultural contexts — remains limited.
• Comparative hepatotoxicity data. While some analyses suggest a lower hepatotoxicity signal for nalmefene compared to naltrexone, robust head-to-head safety data in patients with AUD-related liver disease are not yet available.

These gaps don't undermine confidence in nalmefene — they're simply what honest science looks like at this stage of the evidence base.